Medivation (MDVN) Tops Q2 EPS by 13c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/29/2023
- Wall St ends higher as investors digest economic data ahead of inflation report
- Nike reports blowout earnings in Q1, but revenue falls short of estimates
- Global stock index rises as oil, 10-year yield and dollar pull back
- Micron's mixed guidance weighs on shares but analysts see pullback as a buying opportunity
- Oil eases 1%, reversing rally, on profit taking, interest rate worries
- Westlake Securities Starts Microvision (MVIS) at Hold
- Microsoft CTO discusses NVIDIA, AMD AI chips
- Apple (AAPL) stock dips amid reports that iPhone15 owners complain about overheating
- Bionomics (BNOX) Reports Positive Topline Results from the Phase 2b ATTUNE Clinical Trial of BNC210
- Wall St ends higher as investors digest economic data ahead of inflation report
- Micron, Accenture shares dip premarket; Peloton, Gritstone surge
- After-hours movers: Micron falls following results, Peloton gains on deal with lululemon
- Costco and Zions Bancorporation fall premarket; Rivian and Mattel rise
- Tesla, United Natural Foods, Snap fall premarket; Fisker, DraftKings rise
- After-hours movers: Pliant Therapeutics gains ahead of data, Coty falls on offering
Medivation Reports Second Quarter 2015 Financial Results
August 6, 2015 4:10 PM EDTSAN FRANCISCO, CA -- (Marketwired) -- 08/06/15 -- Medivation, Inc. (NASDAQ: MDVN) today reported its financial results for the second quarter ended June 30, 2015. U.S. net sales of XTANDI (enzalutamide) capsules, as reported by Astellas Pharma Inc., were $298.4 million for the quarter (+108% vs. prior year). Second quarter U.S. net sales increased by 33% compared with first quarter 2015 net sales of $224.0 million. We estimate second quarter 2015 unit demand increased by a low- to mid-teens percentage rate, compared with unit demand in the first quarter 2015. In addition, based on information provided by Astellas, a lower gross-to-net... More
